CBA talks make the 2026 WNBA Draft tough to project, but there are still prospects who deserve to be analyzed.

A look at how this year's finalists compare to each other based on a unique metric that tries to normalize position and era.

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Learn how Ready Capital is repositioning its balance sheet with strategic asset sales, CRE investments, and SBA lending growth.